http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Hyunjung Hwang ),( Ji Young Shin ),( Kyu Ree Park ),( Jae Ouk Shin ),( Kyoung Hwan Song ),( Joonhyung Park ),( Jeong Woong Park ) 대한결핵 및 호흡기학회 2015 Tuberculosis and Respiratory Diseases Vol.78 No.4
Background: The adverse effects of the phosphodiesterase-4 inhibitor roflumilast, appear to be more frequent in clinical practice than what was observed in chronic obstructive pulmonary disease (COPD) clinical trials. Thus, we designed this study to determine whether adverse effects could be reduced by starting roflumilast at half the dose, and then increasing a few weeks later to 500 μg daily. Methods: We retrospectively investigated 85 patients with COPD who had taken either 500 μg roflumilast, or a starting dose of 250 μg and then increased to 500 μg. We analyzed all adverse events and assessed differences between patients who continued taking the drug after dose escalation and those who had stopped. Results: Adverse events were reported by 22 of the 85 patients (25.9%). The most common adverse event was diarrhea (10.6%). Of the 52 patients who had increased from a starting dose of 250 μg roflumilast to 500 μg, 43 (82.7%) successfully maintained the 500 μg roflumilast dose. No difference in factors likely to affect the risk of adverse effects, was detected between the dose-escalated and the discontinued groups. Of the 26 patients who started with the 500 μg roflumilast regimen, seven (26.9%) discontinued because of adverse effects. There was no statistically significant difference in discontinuation rate between the dose-escalated and the control groups (p=0.22). Conclusion: Escalating the roflumilast dose may reduce treatment-related adverse effects and improve tolerance to the full dose. This study suggests that the dose-escalated regimen reduced the rate of discontinuation. However, longer-term and larger-scale studies are needed to support the full benefit of a dose escalation strategy.
Hwang, Eunhee,Mi Lee, Sae,Bak, Sora,Min Hwang, Hee,Kim, Hyunjung,Lee, Hyoyoung Elsevier 2018 Tetrahedron letters: the international organ for t Vol.59 No.44
<P><B>Abstract</B></P> <P>The first methodology of CH arylation of heteroarene via 2D transition metal dichalcogenides that have catalytically active edge functional groups was described. The terminal sulfur groups could effectively catalyze a formation of an azo-linked intermediate with aryl diazonium salts, leading to produce heteroarenes with good yields. This novel methodology using bulk 2D transition metal dichalcogenides that have catalytically active edge functional groups can apply for various reactions to achieve CC bond formation in the fields of heterogeneous catalysis that is easily separable, highly reusable, and inexpensive method.</P> <P><B>Highlights</B></P> <P> <UL> <LI> Unprecedented MoS<SUB>2</SUB> catalyzed for direct CH arylation. </LI> <LI> Catalytically active terminal sulfurs of MoS<SUB>2</SUB> for CH arylation. </LI> <LI> High reusability and simple separation of heterogeneous catalyst. </LI> </UL> </P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>
Hwang, Hyunjung,Shin, Ji Young,Park, Kyu Ree,Shin, Jae Ouk,Song, Kyoung-hwan,Park, Joonhyung,Park, Jeong Woong The Korean Academy of Tuberculosis and Respiratory 2015 Tuberculosis and Respiratory Diseases Vol.78 No.4
Background: The adverse effects of the phosphodiesterase-4 inhibitor roflumilast, appear to be more frequent in clinical practice than what was observed in chronic obstructive pulmonary disease (COPD) clinical trials. Thus, we designed this study to determine whether adverse effects could be reduced by starting roflumilast at half the dose, and then increasing a few weeks later to $500{\mu}g$ daily. Methods: We retrospectively investigated 85 patients with COPD who had taken either $500{\mu}g$ roflumilast, or a starting dose of $250{\mu}g$ and then increased to $500{\mu}g$. We analyzed all adverse events and assessed differences between patients who continued taking the drug after dose escalation and those who had stopped. Results: Adverse events were reported by 22 of the 85 patients (25.9%). The most common adverse event was diarrhea (10.6%). Of the 52 patients who had increased from a starting dose of $250{\mu}g$ roflumilast to $500{\mu}g$, 43 (82.7%) successfully maintained the $500{\mu}g$ roflumilast dose. No difference in factors likely to affect the risk of adverse effects, was detected between the dose-escalated and the discontinued groups. Of the 26 patients who started with the $500{\mu}g$ roflumilast regimen, seven (26.9%) discontinued because of adverse effects. There was no statistically significant difference in discontinuation rate between the dose-escalated and the control groups (p=0.22). Conclusion: Escalating the roflumilast dose may reduce treatment-related adverse effects and improve tolerance to the full dose. This study suggests that the dose-escalated regimen reduced the rate of discontinuation. However, longer-term and larger-scale studies are needed to support the full benefit of a dose escalation strategy.
Poster Session : PS 1236 ; Pulmonology : A Case of Primary Pulmonary Amyloidosis
( Hyunjung Hwang ),( Kyoung Hwan Song ),( Eunkyung Kang ),( Sang Pyo Lee ),( Jeong Woong Park ),( Sung Hwan Jeong ),( Sun Young Kyung ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1
Background: Amyloidosis is a systemic disease of unknown origin which is characterized by extracellular deposit of proteins with a speci. c structural conformation hat gives them a characteristic apple-green birefringence when stained with Congo-red. Isolated pulmonary amyloidosis is a rare localized form of amyloidosis, characterized by amyloid deposits restricted to the lungs. Case: A 79-year-old male was admitted due to hemoptysis and dyspnea for several months. On physical examination, he had crackes in both lungs. The chest tomography showed multiple nodular consolidations and nodules in both upper and right middle lobes and consolidations in both lower lungs. Pulmonary function test revealed moderate restrictive pattern of ventilation. Bronchoscopy showed in. ltrative mucosal lesion and partial obliteration of lateral segmental bronchus of right middle lobe. Pathologic evaluation of the bronchial mucosal biopsy revealed apple-green birefringent amyloid on Congo-red staining. There was no hypergammaglobulinemia on protein electrophoresis and bone marrow biopsy sections showed normocellular. The patient was diagnosed isolated pulmonary amyloidosis with endobronchial involvement. Conclusion: We report a rare case of primary pulmonary amyloidosis presenting with hemoptysis.
Comparison of Machine Learning Models According to Data Trends for Predicting Tomato Growth
Hyunjung Hwang,Hyuntae Lee,Seungwoo Cha,Jihyeon Choi,Hwanyong Choi,Sangjun Chung,Seoheui Lee,Junhyuck Jang,Christopher RETITI DIOP EMANE,Yuna Kim,Jongtae Lim,Kyoungsoo Bok,Jaesoo Yoo 한국콘텐츠학회 2022 한국콘텐츠학회 ICCC 논문집 Vol.2022 No.12
온실 기초의 구조적 안전성 평가를 위한 IMU 센서의 활용
황현정 ( Hyunjung Hwang ),박재성 ( Jaesung Park ),김동석 ( Dongseok Kim ),조석훈 ( Sukhoon Cho ),송지수 ( Jisu Song ),정은지 ( Eunji Jung ) 한국농업기계학회 2023 한국농업기계학회 학술발표논문집 Vol.28 No.1
시설 농업은 내부 환경 제어를 통해 외부 위험요소를 차단하고, 안정적으로 높은 품질의 작물을 생산하여 국내 농업 경쟁력에 이바지한다. 하지만 매년 기상재해로 인한 온실 피해가 빈번히 발생하고 그에 따른 경제적 손실이 막대하다. 시설재배 면적과 농가 인구가 감소하고 재배 기술이 향상됨에 따라, 시설재배 구조물의 안전성 확보가 더욱 요구된다. 농업 시설의 경제적 손실을 최소화하기 위해 온실 기초의 안전성을 평가하고, 기초부분에서 보완된 내재해형 온실을 계획하여 온실 피해를 예방하는 데 초점을 두었다. 본 연구에서는 내재해형 온실을 위해 센서 선정 및 센서의 성능 검증, 데이터 분석 방법을 제안하였다. 현장에서 인력을 통해 온실 기초의 안정성 데이터를 지속적으로 획득하기는 어려우므로, 다양한 센서를 통해 자동으로 실시간 데이터를 계측하고 관리하는 시스템을 구성하고자 하였다. 본 연구는 기초 연구로써 다양한 기상현상을 실내에 재현하여 실험을 진행하였다. 무게가 가벼워 설치가 용이하고, 저렴하지만 우수한 성능의 IMU(관성측정장치) 센서를 통해 회전 방향과 회전 크기, 변위 및 가속도 데이터를 수집하였다. 센서를 통해 수집된 동적 데이터는 오픈소스 라이브러리를 활용하여 3차원 공간에서의 좌표 변동을 추적하고, 이를 분석하였다. 센서의 기본 특성 평가 및 실제 외부 환경에서 사용될 센서의 민감도 분석 등을 사전 조사하여 활용성을 검토하였다. 추후 온실 구조물 기초에 본 센서를 부착하여 구조물의 실제 움직임을 빠르게 감지하고, 외부 기상 조건과 비교 분석함으로써 상관성을 도출하는데 활용하고자 한다.